Since other authors have mentioned the favorable effects of DPP-4 suppression for cancer biology elsewhere [5,6,7,8,9,10], this review mainly focuses on the undesirable effects of DPP-4 inhibition in T2DM patients with cancer, including our preclinical data. The gene discussed is DPP4; the disease is cancer.